IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that on 10 September 2019, John Hall, SVP Corporate Development, exercised 87,647 share options in the Company resulting in the allotment of new ordinary shares. 50,000 of these shares are allotted at a price of 36.5p and 37,647 of these shares are allotted at a price of 49p.
John Hall is interested in 183,094 Ordinary Shares, representing 0.4 per cent of the enlarged issued share capital of the Company following the exercise of options.
Application has been made to the London Stock Exchange for the admission to trading on AIM of 87,647 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options. The New Shares are expected to be admitted to trading on AIM on 16 September 2019.
Total voting rights
Application has been made for admission to trading on AIM of 87,647 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00a.m. on 16 September 2019, following which there will be in total 46,902,294 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
SVP Corporate Development
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary Shares in IXICO plc
Nature of the transaction
Exercise of share options
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
Place of the transaction
Outside of a trading venue
+44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM .
For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...